Diligence memo · auto-generated · as of July 2, 2026

VeraMorph Inc.

VeraMorph Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

VeraMorph Inc. operates in Biotechnology, based in MANSFIELD.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

VeraMorph Inc. has raised $222K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $222K on 2022-08-19.

Most recent recorded round closed around 2022-08-19.

Valuation (modeled)modeled

Provath models VeraMorph Inc. at approximately $3.3M (range $119K–$19M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.01× the median modeled value of Pre-Seed Biotechnology companies in 2022–2024 (185 peers) — value vs value, same stage and era. Within the normal band (101% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 3.9 yr ago; this sector typically re-raises about every 14 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 4% of Biotechnology peers (4291 compared).

Modeled value ranks above 7% of those peers.

Closest niche peers: TissueMill Technologies LLC, Aldebaran Therapeutics, Inc., BullFrog AI Holdings, Inc., Vesicle Therapeutics Inc., TAUC3 Biologics Ltd.

Peoplefiled

1 named person on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.